BCL2L1 and cancer: Akin to our findings with IL11‐Mutein therapy (Putoczki et al, 2013; Stuart et al, 2014), tumors from bazedoxifene‐treated mice had reduced expression of the pro‐survival protein Bcl‐xL, of the proliferative marker cyclin D1 and the cancer cell‐specific mitosis marker survivin (Fig 4F).